Cargando…

Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned

The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) (“the switch”) presented an unprecedented challenge to countries. In order to mitigate the risks associated with country-level delays in implementing the switch, the Global Polio Eradication Initiative p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shendale, Stephanie, Farrell, Margaret, Hampton, Lee M., Harris, Jennifer B., Kachra, Tasleem, Kurji, Feyrouz, Patel, Manish, Ramirez Gonzalez, Alejandro, Zipursky, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853345/
https://www.ncbi.nlm.nih.gov/pubmed/28838171
http://dx.doi.org/10.1093/infdis/jiw577
_version_ 1783306744607277056
author Shendale, Stephanie
Farrell, Margaret
Hampton, Lee M.
Harris, Jennifer B.
Kachra, Tasleem
Kurji, Feyrouz
Patel, Manish
Ramirez Gonzalez, Alejandro
Zipursky, Simona
author_facet Shendale, Stephanie
Farrell, Margaret
Hampton, Lee M.
Harris, Jennifer B.
Kachra, Tasleem
Kurji, Feyrouz
Patel, Manish
Ramirez Gonzalez, Alejandro
Zipursky, Simona
author_sort Shendale, Stephanie
collection PubMed
description The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) (“the switch”) presented an unprecedented challenge to countries. In order to mitigate the risks associated with country-level delays in implementing the switch, the Global Polio Eradication Initiative provided catalytic financial support to specific countries for operational costs unique to the switch. Between November 2015 and February 2016, a total of approximately US$19.4 million in financial support was provided to 67 countries. On average, country budgets allocated 20% to human resources, 23% to trainings and meetings, 8% to communications and advocacy, 9% to logistics, 15% to monitoring, and 5% to waste management. All 67 funded countries successfully switched from tOPV to bOPV during April–May 2016. This funding provided target countries with the necessary catalytic support to facilitate the execution of the switch on an accelerated timeline, and the mechanism offers a model for similar support to future global health efforts, such as the eventual global withdrawal of bOPV.
format Online
Article
Text
id pubmed-5853345
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58533452018-07-01 Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned Shendale, Stephanie Farrell, Margaret Hampton, Lee M. Harris, Jennifer B. Kachra, Tasleem Kurji, Feyrouz Patel, Manish Ramirez Gonzalez, Alejandro Zipursky, Simona J Infect Dis Supplement Article The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV) (“the switch”) presented an unprecedented challenge to countries. In order to mitigate the risks associated with country-level delays in implementing the switch, the Global Polio Eradication Initiative provided catalytic financial support to specific countries for operational costs unique to the switch. Between November 2015 and February 2016, a total of approximately US$19.4 million in financial support was provided to 67 countries. On average, country budgets allocated 20% to human resources, 23% to trainings and meetings, 8% to communications and advocacy, 9% to logistics, 15% to monitoring, and 5% to waste management. All 67 funded countries successfully switched from tOPV to bOPV during April–May 2016. This funding provided target countries with the necessary catalytic support to facilitate the execution of the switch on an accelerated timeline, and the mechanism offers a model for similar support to future global health efforts, such as the eventual global withdrawal of bOPV. Oxford University Press 2017-07-01 2017-07-01 /pmc/articles/PMC5853345/ /pubmed/28838171 http://dx.doi.org/10.1093/infdis/jiw577 Text en © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/3.0/igo This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 IGO (CC BY 3.0 IGO) License (https://creativecommons.org/licenses/by/3.0/igo/) which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Article
Shendale, Stephanie
Farrell, Margaret
Hampton, Lee M.
Harris, Jennifer B.
Kachra, Tasleem
Kurji, Feyrouz
Patel, Manish
Ramirez Gonzalez, Alejandro
Zipursky, Simona
Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned
title Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned
title_full Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned
title_fullStr Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned
title_full_unstemmed Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned
title_short Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned
title_sort financial support to eligible countries for the switch from trivalent to bivalent oral polio vaccine—lessons learned
topic Supplement Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853345/
https://www.ncbi.nlm.nih.gov/pubmed/28838171
http://dx.doi.org/10.1093/infdis/jiw577
work_keys_str_mv AT shendalestephanie financialsupporttoeligiblecountriesfortheswitchfromtrivalenttobivalentoralpoliovaccinelessonslearned
AT farrellmargaret financialsupporttoeligiblecountriesfortheswitchfromtrivalenttobivalentoralpoliovaccinelessonslearned
AT hamptonleem financialsupporttoeligiblecountriesfortheswitchfromtrivalenttobivalentoralpoliovaccinelessonslearned
AT harrisjenniferb financialsupporttoeligiblecountriesfortheswitchfromtrivalenttobivalentoralpoliovaccinelessonslearned
AT kachratasleem financialsupporttoeligiblecountriesfortheswitchfromtrivalenttobivalentoralpoliovaccinelessonslearned
AT kurjifeyrouz financialsupporttoeligiblecountriesfortheswitchfromtrivalenttobivalentoralpoliovaccinelessonslearned
AT patelmanish financialsupporttoeligiblecountriesfortheswitchfromtrivalenttobivalentoralpoliovaccinelessonslearned
AT ramirezgonzalezalejandro financialsupporttoeligiblecountriesfortheswitchfromtrivalenttobivalentoralpoliovaccinelessonslearned
AT zipurskysimona financialsupporttoeligiblecountriesfortheswitchfromtrivalenttobivalentoralpoliovaccinelessonslearned